A Randomized, Double Blinded Controlled Parallel Group Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients undergoing Complex Cardiac Surgery Procedures (ReCePI)

Grants and Contracts Details

StatusActive
Effective start/end date5/24/198/3/25

Funding

  • Cerus Corporation: $757,494.00